Trials / Completed
CompletedNCT04235933
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects
A Phase I, Open-label Study to Evaluate the Pharmacokinetics, and Pharmacodynamics of a Single Dose of Tai Ai Injection in Healthy Adult Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
to evaluate the pharmacokinetics, and pharmacodynamics of a single dose of Tai Ai injection in healthy adult Chinese subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tai Ai(RC18) 80mg | The patient received one treatment of RC18 80mg in the test group |
| BIOLOGICAL | Tai Ai(RC18) 160mg | The patient received one treatment of RC18 160mg in the test group |
| BIOLOGICAL | RC18 240mg | The patient received one treatment of RC18 240mg in the test group |
Timeline
- Start date
- 2019-09-17
- Primary completion
- 2019-12-20
- Completion
- 2019-12-20
- First posted
- 2020-01-22
- Last updated
- 2020-01-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04235933. Inclusion in this directory is not an endorsement.